hypertension

Photo
26.07.2023 • News

Roche Teams up with Alnylam for Antihypertensive Drug

Swiss pharmaceutical company Roche will collaborate with Cambridge, Massachusetts-based US biotech Alnylam Pharmaceuticals to further develop its drug zilebesiran for the treatment of hypertension. The therapeutic, which is in Phase 2 clinical trials, uses the cellular mechanism RNA interference (RNAi) for targeted gene silencing.

Photo
12.01.2023 • News

AstraZeneca Buys CinCor Pharma

AstraZeneca has entered into an agreement to buy CinCor Pharma, a US-based clinical-stage biopharma focused on developing novel treatments for resistant and uncontrolled hypertension as well as chronic kidney disease.

Photo
05.01.2023 • News

Novartis to Pay $245 Million in ’Pay for Delay’ Settlement

Novartis has agreed to pay a total of $245 million to settle lawsuits filed by direct purchasers, indirect purchasers and retailers accusing it of colluding with Par Pharmaceutical to delay the launch of a generic version of its Exforge (valsartan/amlodipine) hypertension drug.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.